These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30419838)

  • 1. Calcium-activated chloride channel regulator 1 as a prognostic biomarker in pancreatic ductal adenocarcinoma.
    Hu D; Ansari D; Zhou Q; Sasor A; Hilmersson KS; Bauden M; Jiang Y; Andersson R
    BMC Cancer; 2018 Nov; 18(1):1096. PubMed ID: 30419838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CLIC1 overexpression is associated with poor prognosis in pancreatic ductal adenocarcinomas.
    Jia N; Dong S; Zhao G; Gao H; Li X; Zhang H
    J Cancer Res Ther; 2016; 12(2):892-6. PubMed ID: 27461670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
    BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low expression of chloride channel accessory 1 predicts a poor prognosis in colorectal cancer.
    Yang B; Cao L; Liu J; Xu Y; Milne G; Chan W; Heys SD; McCaig CD; Pu J
    Cancer; 2015 May; 121(10):1570-80. PubMed ID: 25603912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
    Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
    World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
    Neuzillet C; Couvelard A; Tijeras-Raballand A; de Mestier L; de Gramont A; Bédossa P; Paradis V; Sauvanet A; Bachet JB; Ruszniewski P; Raymond E; Hammel P; Cros J
    Histopathology; 2015 Nov; 67(5):664-76. PubMed ID: 25809563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma.
    Yu R; Li C; Lin X; Chen Q; Li J; Song L; Lin L; Liu J; Zhang Y; Kong W; Ouyang X; Chen X
    Pathol Res Pract; 2017 Aug; 213(8):964-968. PubMed ID: 28559119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
    Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
    BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular subtypes of pancreatic cancer based on miRNA expression profiles have independent prognostic value.
    Namkung J; Kwon W; Choi Y; Yi SG; Han S; Kang MJ; Kim SW; Park T; Jang JY
    J Gastroenterol Hepatol; 2016 Jun; 31(6):1160-7. PubMed ID: 26644397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and clinical significance of HSPA2 in pancreatic ductal adenocarcinoma.
    Zhang H; Gao H; Liu C; Kong Y; Wang C; Zhang H
    Diagn Pathol; 2015 Mar; 10():13. PubMed ID: 25890028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortalin expression in pancreatic cancer and its clinical and prognostic significance.
    Cui X; Li Z; Piao J; Li J; Li L; Lin Z; Jin A
    Hum Pathol; 2017 Jun; 64():171-178. PubMed ID: 28412209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteins of the retinoblastoma pathway, FEN1 and MGMT are novel potential prognostic biomarkers in pancreatic adenocarcinoma.
    Isohookana J; Haapasaari KM; Soini Y; Leppänen J; Karihtala P
    Pathol Res Pract; 2018 Jun; 214(6):840-847. PubMed ID: 29735403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galectin 4 is a biomarker for early recurrence and death after surgical resection for pancreatic ductal adenocarcinoma.
    Hu D; Ansari D; Zhou Q; Sasor A; Said Hilmersson K; Andersson R
    Scand J Gastroenterol; 2019 Jan; 54(1):95-100. PubMed ID: 30663442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
    Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
    Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implication of Sox9 and activated Akt expression in pancreatic ductal adenocarcinoma.
    Xia S; Feng Z; Qi X; Yin Y; Jin J; Wu Y; Wu H; Feng Y; Tao M
    Med Oncol; 2015 Jan; 32(1):358. PubMed ID: 25428381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
    Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
    Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Fermér C; Nilsson O; Seppänen H; Haglund C
    PLoS One; 2015; 10(6):e0129012. PubMed ID: 26053486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological and prognostic significance of ubiquitin-specific peptidase 15 and its relationship with transforming growth factor-β receptors in patients with pancreatic ductal adenocarcinoma.
    Jiang B; Zhou L; Lu J; Wang Y; Liu C; Liang Z; Zhou W; You L; Guo J
    J Gastroenterol Hepatol; 2021 Feb; 36(2):507-515. PubMed ID: 32875609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.